2017-08-14T13:04:02-05:00 2016-09-30 ERNST & YOUNG US LLP 18101 VON KARMAN AVE STE 1700 IRVINE CA 92612 990 2015-10-01 953432210 Beckman Research Institute of the City of Hope % CORNELIS VAN DEN BERG BECK 6262564673 1450 East Duarte Road Duarte CA 91010 CORNELIS VAN DEN BERG Interim CFO 2017-08-14 true KARA ADAMS P00023315 9497942300 2015 2021-01-29 14:40:06Z ROBERT STONE 1500 EAST DUARTE ROAD DUARTE CA 91010 460779050 false X www.cityofhope.org X 1979 CA TO QUICKLY TURN RESEARCH IDEAS INTO NEW TREATMENTS AND CURES THROUGH MEDICAL AND BIOMEDICAL RESEARCH AND DISEASE INVESTIGATION, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. 8 6 1042 0 -1920772 -1920772 279811394 331654992 6190332 7020450 42151167 25921535 2723466 6193185 330876359 370790162 0 0 0 0 108818371 123053508 0 0 3329627 178181339 204322417 286999710 327375925 43876649 43414237 991819363 1113807258 150248331 186654451 841571032 927152807 X THE SPECIFIC AND PRIMARY PURPOSE IS TO ENGAGE DIRECTLY IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH. SEE SCHEDULE O. false false 283290337 7044929 BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE; THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN. SEE SCHEDULE O. 283290337 true true false false false false false false false true true true false false true true false true false false true false false false false false false false false true true false false false false false true false false true false false false false false false true true true false false true 345 0 true 1042 true true true true BD CJ false false false false false false false false X 8 6 false false false false true true true true true false false false true true true true true true true false CA X CORNELIS VAN DEN BERG 6262564673 1500 EAST DUARTE ROAD DUARTE CA 91010 X John Rossi Board Member/Professor 60.0 0.0 X 380562 0 67473 Linda Malkas Board Member/Professor 60.0 0.0 X 431270 0 50810 IRIS ROTHSTEIN BOARD MEMBER 2.0 2.0 X 0 0 0 ERNIE SO BOARD MEMBER 2.0 2.0 X 0 0 0 GARY E FREEDMAN BOARD MEMBER 2.0 0.0 X 0 0 0 BENHAM BADIE MD BOARD MEMBER 2.0 0.0 X 0 0 0 ART NEMIROFF BOARD MEMBER 2.0 0.0 X 0 0 0 Jody Horowitz Marsh Board Member, Chairperson 1.0 4.0 X X 0 0 0 Boriana Farias Asst Treas/VP Treasury 15.0 45.0 X 71510 214531 50328 Gregory Schetina Secretary/General Counsel 15.0 45.0 X 203510 610530 150384 William Sargeant Asst Secretary/COO 15.0 45.0 X 333961 1001882 164896 Richard Magnuson TREASURER/CFO - OUTGOING 15.0 45.0 X 245156 735470 190539 Robert W Stone President and CEO 15.0 45.0 X 548687 1646063 344796 Cornelis van den Berg Interim CFO/Treasurer 15.0 45.0 X 77451 232353 9833 David Horne Chairperson/Professor 60.0 0.0 X 717178 0 52345 Ashley Baker Lee SVP Rsch Ops 60.0 0.0 X 677303 0 38327 Steven Rosen Chief Scientific Officer 34.0 26.0 X 890573 671837 266839 JONATHAN REUTER VP FACILITIES & CONSTRUCTION 24.0 36.0 X 144911 217365 34245 Michael Friedman Emeritus Cancer Ctr Director 6.0 54.0 X 71600 644393 42411 Debra Fields Chief Risk Officer 15.0 45.0 X 226726 680176 143723 Harlan Levine COH Medical Foundation CE 3.0 57.0 X 338215 1326465 272935 Lisa Stockmon Chief Marketing & Comm Officer 15.0 45.0 X 152014 456044 67314 Larry Kwak Associate Professor 60.0 0.0 X 1114350 0 61137 Wael Fakhry Former Officer 12.0 48.0 X 108269 433074 38024 Valerie Bingham Former Officer 15.0 45.0 X 71976 215930 46384 STEPHANIE NEUVIRTH CHIEF HR OFFICER - OUTGOING 0.0 0.0 X 100849 302547 21860 Larry Couture VP CATD 60.0 0.0 X 547102 0 35221 7453173 9388660 2149824 187 true true false Cancer Prevention Institute of Cali 2201 Walnut Avenue FREMONT CA 94538 Research Services 1202998 University of Southern California File No 52095 LOS ANGELES CA 94538 Research Services 1015270 Regents University of California Ir Biological Scienses III Suite 1400 IRVINE CA 92697 Research Services 901031 Jones Day 555 South Flower Street 50th Floor LOS ANGELES CA 90071 Legal Services 857433 IRELL MANELLA LLP PO BOX 51167 LOS ANGELES CA 90051 Legal Services 664992 52 265850929 59381863 6422200 15367 331654992 OTHER RESEARCH ACTIVITIES 541990 6270446 6270446 ACADEMIC STAFF REVENUE 611310 47238 47238 SPECIALIZED LAB REVENUE 541900 590184 590184 RENTAL INCOME - PROGRAM SERVICE 721310 112582 112582 7020450 17088139 17088139 0 8089478 8089478 0 0 0 98822284 89988888 8833396 8833396 8833396 0 0 0 INVESTMENT INCOME FROM K-1'S 525990 -1920772 -1920772 MISCELLANEOUS REVENUE 900004 24479 24479 -1896293 370790162 7044929 -1920772 34011013 0 0 0 0 4348131 1708105 2469617 170409 157053 157053 93999276 80381108 11598601 2019567 6477051 5646549 689251 141251 12023237 10156473 1600722 266042 6048760 4997349 918822 132589 0 7412100 6658608 578064 175428 228910 228910 0 0 2433368 2433368 20632052 14676564 5862784 92704 4282710 4282710 30375828 26935298 3386301 54229 3951926 1065244 2883672 3010 0 6852379 6302745 439642 109992 1946169 1534487 411682 0 430322 208408 221914 4865828 4123931 741897 0 14914036 14022901 748031 143104 563309 521383 28093 13833 ROYALTY REVENUE SHARING 102097487 102097487 DUES AND SUBSCRIPTIONS 1651196 1427803 223393 TAXES AND LICENSES 621868 362657 251813 7398 OTHER MISCELLANEOUS 1062929 463237 599621 71 327375925 283290337 40755961 3329627 15820813 13608179 2834168 3280436 9503143 16616776 0 0 448161 435407 0 0 1403464 3676745 0 0 2989220 2259780 425339292 158206758 223419386 267132534 311001813 324921676 423487255 475884770 0 0 0 0 911940 5990955 991819363 1113807258 17844686 35865711 0 0 9647766 16507861 54562287 53181277 0 0 0 0 50000000 50000000 0 16717740 18193592 14381862 150248331 186654451 X 823478933 907711717 4289299 5607923 13802800 13833167 841571032 927152807 991819363 1113807258 X 43414237 45200276 -3032738 X false true X true true true X CITY OF HOPE NATIONAL MEDICAL CENTER DUARTE CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 562143821 30367 51317174 0 648491 0 612842871 576279312 40694 -13645494 0 530691 0 562143821 514729850 20552 61593960 0 65050 0 576279312 455249503 20000 59716262 0 255945 0 514729820 393755522 25000 61930306 0 461325 0 455249503 0.96820 0.02260 0.00920 false false 2592400 9736039 12328439 246431255 83426303 163004952 8572 8572 115835483 74771883 41063600 50735543 50735543 267132534 ALTERNATIVE INVESTMENTS 475884770 F 475884770 0 INTEREST RATE SWAP LIABILITY 8488886 BOND ISSUANCE PREMIUM 2215893 DUE TO AFFILIATES 2193241 WORKERS COMPENSATION LIABILITY 1483842 14381862 X SCHEDULE D, PART V, LINE 4 ENDOWMENT FUNDS: BECKMAN RESEARCH INSTITUTE HAS BOARD DESIGNATED ASSETS or QUASI-ENDOWMENT FUNDS and other permanent endowment funds THAT ARE AVAILABLE TO FUND FUTURE RESEARCH, AND CAPITAL AND EXPANSION NEEDS AS DETERMINED BY THE MANAGEMENT AND THE BOARD OF DIRECTORS. SCHEDULE D, PART X, LINE 2 FASB ASC 740 DISCLOSURE: THE FOLLOWING PARAGRAPH IS FROM THE CONSOLIDATED CITY OF HOPE AND AFFILIATES (CITY OF HOPE, CITY OF HOPE AUXILIARIES, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION AND THE BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE) AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2016. FINANCIAL ACCOUNTING STANDARDS BOARD (FASB), ACCOUNTING STANDARDS CODIFICATION ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. FASB ASC 740 ALSO PROVIDES GUIDANCE ON DERECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE GUIDANCE CONTAINED IN FASB ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITIES FOR TAX BENEFITS, INTEREST OR PENALTIES ACCRUED AT SEPTEMBER 30, 2016 AND 2015. Central America and the Caribbean Investments 105176273 Central America and the Caribbean 2 Program Services Research Symposiums 2668 East Asia and the Pacific 30 Program Services Research Symposiums 115831 Europe (Including Iceland and Greenland) 49 Program Services Research Symposiums 99937 Middle East and North Africa 3 Program Services Research Symposiums 9141 North America 20 Program Services Research Symposiums 26270 South America 2 Program Services Research Symposiums 1040 Sub-Saharan Africa 4 Program Services Research Symposiums 7229 89 110 105438389 105438389 true false true true true false SCHEDULE F, PART I, LINE 3 ACTIVITIES PER REGION: INVESTMENT ACTIVITIES OF THE BECKMAN RESEARCH INSTITUTE INCLUDE INVESTMENTS IN MULTIPLE VEHICLES THAT PROVIDE INVESTMENT INCOME AND RETURNS TO THE INSTITUTION TO FURTHER ITS MISSION AND PROGRAMS. AS A RESULT, THERE ARE INVESTMENTS HELD IN OFFSHORE HEDGE FUNDS, MAINLY REGISTERED AS CAYMAN EXEMPTED CORPORATIONS. THESE INVESTMENTS HELP MITIGATE RISK IN THE PORTFOLIO AND REPRESENT APPROXIMATELY 12.9% OF BECKMAN RESEARCH INSTITUTE'S OVERALL CASH AND INVESTMENT PORTFOLIO. THE BECKMAN RESEARCH INSTITUTE HAS HOLDINGS THAT INCLUDE EQUITY COMINGLED FUNDS THAT INVEST PRIMARILY IN MARKETABLE EQUITY SECURITIES. THESE FUNDS ARE SUBJECT TO CERTAIN NOTICE REQUIREMENTS, BUT CAN BE LIQUIDATED AT LEAST MONTHLY. ALTERNATIVE INVESTMENTS ALSO INCLUDE HEDGE FUNDS AND LIMITED PARTNERSHIP FUNDS INVESTED IN REAL ESTATE AND NATURAL RESOURCES, MASTER LIMITED PARTNERSHIPS, PRIVATE EQUITY AND PRIVATE REAL ASSET FUNDS. THESE INVESTMENTS HAVE BEEN INCLUDED IN FORM 990, PART X, LINE 12. RESEARCH SYMPOSIA CONSIST OF SCIENTIFIC MEETINGS THAT BECKMAN RESEARCH INSTITUTE PRINCIPAL INVESTIGATORS AND OTHER RESEARCH STAFF ATTEND FOR EDUCATIONAL, RESEARCH AND SCIENTIFIC PURPOSES AND TO PRESENT AND SHARE RESEARCH OBJECTIVES AND RESULTS. RESEARCH HAS A GLOBAL REACH AND RESEARCH SYMPOSIA ARE OFTEN CONDUCTED IN THE VARIOUS REGIONS IDENTIFIED IN SCHEDULE F. CITY OF HOPE SUPPORTS ATTENDANCE OF OUR RESEARCH STAFF AT THESE SYMPOSIA. EMPLOYEE TRAVELERS MAY MAKE MULTIPLE TRIPS TO THE SAME REGION OR TO MULTIPLE REGIONS DURING A FISCAL YEAR. IN THE CASE WHERE THE SAME EMPLOYEE TRAVELER MADE MORE THAN ONE TRIP TO THE SAME REGION, THEY ARE ONLY COUNTED ONE TIME AS A TRAVELER TO THAT REGION. IF THE SAME EMPLOYEE TRAVELER TRAVELS TO MORE THAN ONE REGION, THAT INDIVIDUAL IS COUNTED ONLY ONCE IN EACH REGION VISITED. THE TOTAL TRAVELERS ON LINE 3A, HOWEVER, ONLY COUNTS THE SAME TRAVELER ONCE IN THE GRAND TOTAL. AS A RESULT THE TOTAL TRAVELERS PER REGION WILL NOT ADD UP TO THE TOTAL ON LINE 3A. WE HAD 15 INSTANCES IN WHICH THE SAME TRAVELER TRAVELED TO MULTIPLE REGIONS DURING THE FISCAL YEAR ENDING SEPTEMBER 30, 2016. THE BECKMAN RESEARCH INSTITUTE DOES NOT HAVE ANY PHYSICAL PRESENCE OR EMPLOYEES OUTSIDE OF THE UNITED STATES. THE BECKMAN RESEARCH INSTITUTE'S REPUTATION AS A WORLD CLASS RESEARCH AND TREATMENT FACILITY IS INTERNATIONALLY RECOGNIZED. AS A RESULT OF THIS RECOGNITION, THE BECKMAN RESEARCH INSTITUTE RECEIVES DONATIONS AND GRANTS FROM PERSONS AND CORPORATIONS OUTSIDE OF THE UNITED STATES. SCHEDULE F, PART I, COLUMN F EXPENDITURES ARE DETERMINED USING THE ACCRUAL METHOD OF ACCOUNTING. X false true false false false false false true false John Rossi Board Member/Professor 319800 0 15704 0 45058 0 39750 0 27723 0 448035 0 0 0 Linda Malkas Board Member/Professor 361692 0 23090 0 46488 0 39750 0 11060 0 482080 0 0 0 David Horne Chairperson/Professor 456825 0 170912 0 89441 0 21760 0 30585 0 769523 0 0 0 Boriana Farias Asst Treas/VP Treasury 57695 173086 13549 40647 266 798 6002 18004 6581 19741 84093 252276 0 0 Gregory Schetina Secretary/General Counsel 104532 313597 84671 254013 14307 42920 29312 87935 8284 24853 241106 723318 22444 67331 William Sargeant Asst Secretary/COO 155905 467714 125429 376288 52627 157880 36357 109070 4867 14602 375185 1125554 66402 199206 Michael Friedman Emeritus Cancer Ctr Director 25178 226597 13804 124237 32618 293559 2112 19011 2129 19159 75841 682563 0 0 Richard Magnuson TREASURER/CFO - OUTGOING 141137 423413 102616 307847 1403 4210 44029 132086 3606 10818 292791 878374 28863 86588 Robert W Stone President and CEO 239687 719061 266193 798580 42807 128422 77111 231334 9088 27263 634886 1904660 64429 193286 Wael Fakhry Former Officer 77714 310855 6397 25588 24158 96631 1646 6584 5959 23835 115874 463493 12172 48688 Ashley Baker Lee SVP Rsch Ops 354090 0 216016 0 107197 0 8230 0 30097 0 715630 0 59979 0 Debra Fields Chief Risk Officer 97192 291576 121316 363947 8218 24653 27845 83535 8086 24257 262657 787968 20884 62653 Harlan Levine COH Medical Foundation CE 39533 751122 298235 566859 447 8484 12235 232469 1412 26819 351862 1585753 8063 153200 Steven Rosen Chief Scientific Officer 452820 341601 380275 286875 57478 43361 136007 102601 16092 12139 1042672 786577 0 0 Lisa Stockmon Chief Marketing & Comm Officer 96339 289019 37500 112500 18175 54525 12066 36197 4763 14288 168843 506529 0 0 Valerie Bingham Former Officer 59268 177805 10880 32642 1828 5483 4893 14680 6703 20108 83572 250718 0 0 Cornelis van den Berg Interim CFO/Treasurer 46694 140084 30434 91302 323 967 0 0 2458 7375 79909 239728 0 0 Larry Kwak Associate Professor 475679 0 565000 0 73671 0 37917 0 23220 0 1175487 0 0 0 STEPHANIE NEUVIRTH CHIEF HR OFFICER - OUTGOING 62589 187766 0 0 38260 114781 1941 5824 3524 10571 106314 318942 0 0 JONATHAN REUTER VP FACILITIES & CONSTRUCTION 114979 172468 28933 43399 999 1498 3292 4938 10406 15609 158609 237912 0 0 Larry Couture VP CATD 382059 0 109337 0 55706 0 21760 0 13461 0 582323 0 0 0 SCHEDULE J, PART I, LINE 1A The organization permits first class travel for certain officers, directors and key executives in limited circumstances when specified travel criteria are met. SCHEDULE J, PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER OF THE ORGANIZATION IS NOT COMPENSATED BY THE BECKMAN RESEARCH INSTITUTE BUT BY THE MEDICAL CENTER. CHIEF EXECUTIVE OFFICER COMPENSATION IS ESTABLISHED BY THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS. ALL SOURCES INDICATED IN LINE 3 ARE UTILIZED BY THIS COMMITTEE TO SET SUCH COMPENSATION. SEE NARRATIVE FOR SCHEDULE O, PART VI, LINE 15A. SCHEDULE J, PART I, LINE 4B THE BECKMAN RESEARCH INSTITUTE HAS AN EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS A NON-QUALIFIED SECTION 457(F) PLAN. THE PLAN IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B(III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL, AND FICA TAXES. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING CALENDAR YEAR 2015 THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: VALERIE BINGHAM $ 1,754 PAUL CONOCENTI $47,153 WAEL FAKHRY $31,603 DEBRA FIELDS $ 5,602 DAVID HORNE $ 7,550 ASHLEY LEE $33,923 STEPHANIE NEUVIRTH $14,319 WILLIAM SARGEANT $83,625 GREGORY SCHETINA $ 5,380 ROBERT STONE $28,858 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS' INCOME ON SCHEDULE J, PART II, COLUMN B(III). WAEL FAKHRY AND STEPHANIE NEUVIRTH ENDED EMPLOYMENT WITH CITY OF HOPE DURING THE CALENDAR YEAR ENDING DECEMBER 31, 2015 AND RECEIVED DISTRIBUTIONS FROM THE PLAN TOTALING $61,484 AND $137,759, RESPECTIVELY. THESE AMOUNTS HAVE BEEN REPORTED AS TAXABLE COMPENSATION IN EITHER THE CURRENT YEAR OR IN A PRIOR YEAR 990 IN SCHEDULE J, PART II, COLUMN B(III). SCHEDULE J, PART I, LINE 7 The Beckman Research Institute Executives and some key employees are eligible to receive incentive compensation under an Annual Incentive Plan (AIP) tied to two (2) key indicators and two or more individual objectives. The key indicators reflect key areas of strategic focus and the exempt healthcare mission of the City of Hope and affiliates and are both financial and non-financial. The potential incentive compensation is based on a weighted average among all indicators and is paid as a percentage of each individual participants base compensation. The key indicators are weighted at 30%, while the individual objectives are weighted at 70%. The AIP is under the control of and administered by the independent directors serving on the Executive Compensation and Governance Committee. To be eligible, the participants in the AIP must be employed by the Beckman Research Institute at the time of the incentive plan payment, and be meeting or exceeding performance expectations. City of Hope may in its discretion cancel all or a portion of any incentive plan payment or award to any participant, whether before or following payment of such award, subject to compliance with applicable law, under these circumstances (Cancellation Policy): A) An incentive plan payment or award is made for a fiscal period and City of Hope subsequently restates or otherwise adjusts the annual performance measurement calculation in a manner that would reduce the size of the award or payment, or; B) An incentive plan payment or award is made for fiscal period and City of Hope subsequently determines that one or more of the annual performance measurement calculations on which the award is based or is paid are materially inaccurate. During calendar year 2015 City of Hope paid the incentive compensation earned for fiscal year 2015 and these amounts have been reported in Schedule J, Part II, Column B(II). The Beckman Research Institute has an Executive Long Term Incentive Plan (LTI) for certain executives that is designed to drive long-term organizational performance and transformation by aligning executives with the multi-year strategic plan and incentivizing them for achieving key organizational and strategic objectives and goals. With three-year vesting periods, the LTI also provides a means for retaining key executive talent. The initial performance period of the plan (Cycle 1) runs from October 1, 2012 through September 30, 2015, with a new three year performance period beginning each October 1 thereafter (e.g., Cycle 2 runs from October 1, 2013 through September 30, 2016). To be eligible, the participants in the LTI must be employed by the City of Hope at the time of the incentive plan payment, and be meeting or exceeding performance expectations. While the LTI does meet the requirements for a substantial risk of forfeiture, as of the calendar year ending December 30, 2015, 9 months of year two plan Cycle 2, 3 months of year three plan Cycle 2 and 3 months of year three plan Cycle 2; 9 months of year 1 plan Cycle 4 of the potential LTI amounts have been estimated and accrued during the current tax year and are reported as deferred compensation to the plan participants in Schedule J, Part II, Column C. THE LTI IS SUBJECT TO THE SAME CANCELLATION POLICY AS THE AIP DESCRIBED ABOVE. ADDITIONALLY, CITY OF HOPE MADE CHANGES TO ITS VACATION AND HOLIDAY ACCRUAL POLICIES DURING CALENDAR YEAR 2015 THAT REDUCED THE NUMBER OF HOURS AN ELIGIBLE EMPLOYEE COULD CARRY AT ANY TIME. THOSE INDIVIDUALS WHOSE ACCUMULATED HOURS EXCEEDED THE NEW MAXIMUM ACCRUAL RECEIVED A ONE-TIME PAYOUT OF THOSE ACCRUED HOURS. THIS PAYOUT HAS BEEN REFLECTED AS REPORTABLE COMPENSATION IN SCHEDULE J, PART II, COLUMN B(III). SCHEDULE J, PART II JOHN J. ROSSI, PHD, AND LINDA MALKAS, PHD, ARE MEMBERS OF THE BOARD OF DIRECTORS OF THE BECKMAN RESEARCH INSTITUTE AND ARE ALSO EMPLOYEES OF AND COMPENSATED BY THE BECKMAN RESEARCH INSTITUTE. DR. ROSSI IS A PROFESSOR AND DIRECTOR OF MOLECULAR MEDICINE AND THE DEAN OF THE CITY OF HOPE'S IRELL AND MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. DR. MALKAS IS A PROFESSOR AND DEPUTY DIRECTOR FOR BASIC RESEARCH FOR THE CANCER CENTER. NEITHER DR. ROSSI NOR DR. MALKAS ARE COMPENSATED FOR THEIR SERVICES AS A MEMBER OF THE BECKMAN RESEARCH INSTITUTE'S BOARD OF DIRECTORS. EMPLOYEE COMPENSATION FOR BOTH OF THESE INDIVIDUALS IS LISTED ON SCHEDULE J, PART II AND FORM 990, PART VII, SECTION A. A CALIF HLTH FACLTY FIN AUTH (SEE PART VI) 521643828 13033LN37 2012-11-14 57928340 REFUNDING ISSUE/CAPITAL PROJECTS false false false A 0 0 57928742 0 0 0 534551 0 0 9853233 47540958 0 2014 true false true true A false true true true true true 0.01100 0.01100 false false false true A false true true true UNION BNWELLS FARGO 30. false false false 0 false true A true SCHEDULE K, PART I, LINE A AN ELECTION WAS MADE UNDER 1.150-1(C)(3) TO TREAT THE BOND ISSUE AS TWO SEPARATE ISSUES AND WAS REPORTED ON TWO SEPARATE FORMS 8038. ONE WAS FOR REFUNDING THE CITY OF HOPE NATIONAL MEDICAL CENTER'S CITY OF DUARTE CERTIFICATES OF PARTICIPATION SERIES 1999A AND THE OTHER WAS FOR REFUNDING (1) THE CITY OF HOPE NATIONAL MEDICAL CENTER PROJECT SERIES 2006A,B,C ISSUES AND (2) THE BECKMAN RESEARCH INSTITUTE'S 2007 CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY ISSUE. THIS SECOND FORM 8038 REPORTED AN ISSUE PRICE OF $198,734,018. FOR PURPOSES OF SCHEDULE K REPORTING, THE BECKMAN RESEARCH INSTITUTE IS REPORTING AN ALLOCABLE AMOUNT OF THE ISSUE PRICE AND EXPENDITURES. BECKMAN RESEARCH INSTITUTE IS REPORTING AN ISSUE PRICE OF $57,928,340, WHILE THE CITY OF HOPE NATIONAL MEDICAL CENTER IS REPORTING AN ISSUE PRICE OF $140,805,678. SCHEDULE K, PART I, LINE A COLUMN (F) THE 2012 ISSUE REFUNDED BECKMAN RESEARCH INSTITUTE'S TAX EXEMPT PRIVATE PLACEMENT ISSUED ON JULY 12, 2007 THROUGH CALIFORNIA ENTERPRISE DEVELOPMENT AUTHORITY. SCHEDULE K, PART II, LINE 11, COLUMN A THE OTHER SPENT PROCEEDS ARE THE REFUNDING PROCEEDS OF THE ISSUE WHICH ARE NO LONGER IN ESCROW. SCHEDULE K, PART IV CITY OF HOPE COMPLETED THE REBATE COMPUTATION ON SEPTEMBER 3, 2015 WITH NO REBATE LIABILITY DUE. Linda Malkas Director Mtg Subsidy X 500000 435407 false true true 435407 KIRSTEN ROOD SPOUSE OF A KEY EMPLOYEE 64869 EMPLOYEE COMPENSATION false SYLVANA COUTURE SPOUSE OF A KEY EMPLOYEE 20073 EMPLOYEE COMPENSATION false ROBERT HICKEY SPOUSE OF BOARD MEMBER 205984 EMPLOYEE COMPENSATION false DANIEL ROSSI CHILD OF BOARD MEMBER 39658 EMPLOYEE COMPENSATION false SCHEDULE L, PART II LOANS TO/FROM INTERESTED PERSONS: LINDA H. MALKAS, PHD, WAS PROVIDED A MORTGAGE ASSISTANCE LOAN AS PART OF HER RECRUITMENT BY THE BECKMAN RESEARCH INSTITUTE. DR. MALKAS MAKES MONTHLY PRINCIPAL AND INTEREST PAYMENTS ON THIS LOAN AND IS CURRENT WITH ALL PAYMENTS. THE LOAN BEARS INTEREST AT 2.42 PERCENT PER ANNUM AND IS SECURED BY REAL PROPERTY IN THE STATE OF CALIFORNIA. THE NOTE IS DUE IN FULL FOR ANY REMAINING OUTSTANDING PRINCIPAL AND INTEREST THE EARLIER OF MAY 9, 2021 OR THE TERMINATION OF DR. MALKAS' EMPLOYMENT. FORM 990, PART III LINE 1 ORGANIZATION'S MISSION - CONTINUATION: BECKMAN RESEARCH INSTITUTE'S MISSION IS TO SUPPORT INNOVATIVE AND CREATIVE RESEARCH AND TO EDUCATE FUTURE SCIENTISTS IN THE BIOLOGICAL SCIENCES. RESEARCH IS OF THE HIGHEST CALIBER AND DIRECTED TO AN UNDERSTANDING OF THE MOLECULES AND PROCESSES OF LIFE, INCLUDING THOSE PROCESSES IMPORTANT TO THE CAUSES, PREVENTION AND CURE OF HUMAN DISEASE. BECKMAN RESEARCH INSTITUTE IS PART OF AN INTEGRATED SYSTEM THAT COMBINES BENCH AND CLINICAL RESEARCH ACTIVITIES DIRECTLY WITH PATIENT CARE, IN BOTH AN IN-PATIENT AND OUT-PATIENT SETTING. THIS INTEGRATED SYSTEM KNOWN AS CITY OF HOPE COLLECTIVELY REFERS TO CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, AND CITY OF HOPE AUXILIARIES. AS AN INNOVATIVE BIOMEDICAL RESEARCH, TREATMENT AND EDUCATIONAL INSTITUTION, WE ARE COMMITTED TO TRANSFORMING THE FUTURE OF HEALTH. EVERY DAY WE TURN SCIENCE INTO PRACTICAL BENEFIT. WE TURN HOPE INTO REALITY. WE ACCOMPLISH THIS THROUGH EXQUISITE CARE, INNOVATIVE RESEARCH, AND VITAL EDUCATION FOCUSED ON ELIMINATING CANCER, DIABETES AND OTHER LIFE-THREATENING DISEASES. CITY OF HOPE IS GUIDED BY A COMPASSIONATE, PATIENT-CENTERED PHILOSOPHY AND SUPPORTED BY A NATIONAL FOUNDATION OF PHILANTHROPY. FORM 990, PART III, LINE 4A PROGRAM SERVICE ACCOMPLISHMENTS - CONTINUATION: RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN MOLECULAR GENETICS AND CELLULAR BIOLOGY, STUDYING BIOLOGICAL PROCESSES, CELL DIFFERENTIATION AND EARLY DEVELOPMENT, CELLULAR SIGNALING, RNA PROCESSING AND GENOMIC STRUCTURE. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE - ANALYZING PATIENTS' UNIQUE GENETIC PROFILES TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES TO MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT. FORM 990, PART IV, QUESTION 13 AND SCHEDULE E THE BECKMAN RESEARCH INSTITUTE IS ENGAGED IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL AND SCIENTIFIC RESEARCH. BECKMAN RESEARCH INSTITUTE OPERATES A GRADUATE SCHOOL AND COMPLIES WITH REV. PROC. 75-50 EVEN THOUGH THE OPERATIONS OF THE GRADUATE SCHOOL IS LESS THAN 2% OF THE ORGANIZATION'S TOTAL EXPENSES. DUE TO LIMITATIONS IN THE 990 RETURN SOFTWARE APPLICATION, WE ARE UNABLE TO PROVIDE OUR RESPONSES DIRECTLY ON SCHEDULE E, THEREFORE, THE FOLLOWING RESPONDS TO THE QUESTIONS IN THE SCHEDULE E SCHOOLS QUESTIONNAIRE: 1. DOES THE ORGANIZATION HAVE A RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS BY STATEMENT IN ITS CHARTER, BYLAWS, OTHER GOVERNING INSTRUMENT, OR IN A RESOLUTION OF ITS GOVERNING BODY? "YES" 2. DOES THE ORGANIZATION INCLUDE A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY TOWARD STUDENTS IN ALL ITS BROCHURES, CATALOGUES, AND OTHER WRITTEN COMMUNICATIONS WITH THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 3. HAS THE ORGANIZATION PUBLICIZED ITS RACIALLY NONDISCRIMINATORY POLICY THROUGH NEWSPAPER OR BROADCAST MEDIA DURING THE PERIOD OF SOLICITATION FOR STUDENTS, OR DURING THE REGISTRATION PERIOD IF IT HAS NO SOLICITATION PROGRAM, IN A WAY THAT MAKES THE POLICY KNOWN TO ALL PARTS OF THE GENERAL COMMUNITY IT SERVES? IF YES, PLEASE DESCRIBE, IF NO, PLEASE EXPLAIN. "NO." THE GRADUATE SCHOOL CUSTOMARILY DRAWS A SUBSTANTIAL PERCENTAGE OF ITS STUDENTS FROM LARGE GEOGRAPHIC SECTIONS OF THE UNITED STATES AND INTERNATIONALLY, AND FOLLOWS A RACIALLY NONDISCRIMINATORY POLICY AS DEMONSTRATED BY ITS CURRENT ENROLLMENT OF STUDENTS OF RACIAL MINORITY GROUPS IN MEANINGFUL NUMBERS. ACCORDINGLY, THE GRADUATE SCHOOL SATISFIES THE PUBLICITY REQUIREMENTS OF SECTION 4.03 BY COMPLYING WITH SECTION 4.02 IN THAT IT INCLUDES A STATEMENT OF ITS RACIALLY NONDISCRIMINATORY POLICY AS TO STUDENTS IN ITS CATALOGUES AND ON THE ORGANIZATION'S WEBSITE. 4. DOES THE ORGANIZATION MAINTAIN THE FOLLOWING: 4A. RECORDS INDICATING THE RACIAL COMPOSITION OF THE STUDENT BODY, FACULTY, AND ADMINISTRATIVE STAFF? "YES" 4B. RECORDS DOCUMENTING THAT SCHOLARSHIPS AND OTHER FINANCIAL ASSISTANCE ARE AWARDED ON A RACIALLY NONDISCRIMINATORY BASIS? "YES" 4C. COPIES OF ALL CATALOGUES, BROCHURES, ANNOUNCEMENTS, AND OTHER WRITTEN COMMUNICATIONS TO THE PUBLIC DEALING WITH STUDENT ADMISSIONS, PROGRAMS, AND SCHOLARSHIPS? "YES" 4D. COPIES OF ALL MATERIAL USED BY THE ORGANIZATION OR ON ITS BEHALF TO SOLICIT CONTRIBUTIONS? "YES" 5. DOES THE ORGANIZATION DISCRIMINATE BY RACE IN ANY WAY WITH RESPECT TO: 5A. STUDENT'S RIGHTS OR PRIVILEGES? "NO" 5B. ADMISSIONS POLICIES? "NO" 5C. EMPLOYMENT OF FACULTY OR ADMINISTRATIVE STAFF? "NO" 5D. SCHOLARSHIPS OR OTHER FINANCIAL ASSISTANCE? "NO" 5E. EDUCATIONAL POLICIES? "NO" 5F. USE OF FACILITIES? "NO" 5G. ATHLETIC PROGRAMS? "NO" 5H. OTHER EXTRACURRICULAR ACTIVITIES? "NO" 6A. DOES THE ORGANIZATION RECEIVE ANY FINANCIAL AID OR ASSISTANCE FROM A GOVERNMENTAL AGENCY? "NO" 6B. HAS THE ORGANIZATION'S RIGHT TO SUCH AID EVER BEEN REVOKED OR SUSPENDED? "NO" 7. DOES THE ORGANIZATION CERTIFY THAT IT HAS COMPLIED WITH THE APPLICABLE REQUIREMENTS OF SECTIONS 4.01 THROUGH 4.05 OF REV. PROC. 75-50, 1975-2C.B. 587, COVERING RACIAL NONDISCRIMINATION? "YES" FORM 990, PART VI, SECTION A, LINE 6 AND 7A THE SOLE CORPORATE MEMBER, CITY OF HOPE (95-3435919), ELECTS THE BOARD OF DIRECTORS TO BECKMAN RESEARCH INSTITUTE. FORM 990, PART VI, SECTION A, LINE 7B CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF BECKMAN RESEARCH INSTITUTE, INCLUDING: BORROW MONEY IN THE NAME OF BECKMAN RESEARCH INSTITUTE OR UTILIZING PROPERTY OWNED BY BECKMAN RESEARCH INSTITUTE AS SECURITY FOR SUCH LOANS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE ANY OF THE CLAIMS OR DEBTS TO BECKMAN RESEARCH INSTITUTE EXCEPT ON PAYMENT IN FULL, OR ARBITRATE OR CONSENT TO THE ARBITRATION OF ANY DISPUTE OR CONTROVERSY OF BECKMAN RESEARCH INSTITUTE; MAKE, EXECUTE OR DELIVER ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR ANY BOND, CONFESSION OF JUDGMENT, CHATTEL MORTGAGE, SECURITY AGREEMENT, DEED, GUARANTY, INDEMNITY BOND, SURETY BOND, OR CONTRACT TO SELL OR BILL OF SALE OF THE PROPERTY OF BECKMAN RESEARCH INSTITUTE; ACQUIRE, PURCHASE, DEVELOP, IMPROVE, SELL, LEASE, OR MORTGAGE ANY CORPORATE REAL ESTATE OR ANY INTEREST THEREIN OR ENTER INTO ANY CONTRACT FOR ANY SUCH PURPOSES; OR MAKE ANY LOAN, INVESTMENT, TRANSFER OR DISPOSITION OF ANY ASSETS OF BECKMAN RESEARCH INSTITUTE OR ENTER INTO ANY CONTRACT OR INCUR ANY LIABILITIES ON BEHALF OF BECKMAN RESEARCH INSTITUTE OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS RELATING TO ITS NORMAL DAILY OPERATION; OR ESTABLISH CAPITAL AND OPERATING BUDGETS OR ADOPT MATERIAL CHANGES THERETO; OR ANY ACTION THAT COULD REASONABLY BE EXPECTED TO HAVE A MATERIAL ADVERSE EFFECT ON THE 501(C)(3) STATUS OF TAX-EXEMPT BONDS OF CITY OF HOPE AND AFFILIATES. THE FOLLOWING REQUIRE GOVERNING BODY APPROVAL (AS WELL AS THE APPROVAL OF THE SOLE CORPORATE MEMBER): THE ADOPTION OF, OR MATERIAL CHANGE IN, THE MISSION OF BECKMAN RESEARCH INSTITUTE; SALE OR DISPOSITION OF ALL OR SUBSTANTIALLY ALL ASSETS; MERGER AND ITS PRINCIPAL TERMS (AND ANY AMENDMENT TO THOSE TERMS); DISSOLUTION OF THE CORPORATION; ADOPTION OF OPERATING AND CAPITAL BUDGETS; ACQUISITIONS AND CAPITAL EXPENDITURES MEETING A CERTAIN FINANCIAL THRESHOLD; BORROWINGS, GUARANTIES, LOANS, AND BOND ISSUANCE MEETING A CERTAIN FINANCIAL THRESHOLD; CREATION OF A NEW (OR ACQUISITION OF A CONTROLLING INTEREST IN AN EXISTING) CORPORATION, PARTNERSHIP OR LIMITED LIABILITY COMPANY; AND ADOPTION OF OR AMENDMENTS TO INDIVIDUAL CORPORATE INVESTMENT GUIDELINES. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CITY OF HOPE, WHICH ASSISTS THE BECKMAN RESEARCH INSTITUTE'S BOARD IN FULFILLING ITS RESPONSIBILITIES REGARDING FINANCIAL, ACCOUNTING, AND CORPORATE COMPLIANCE MATTERS OF BECKMAN RESEARCH INSTITUTE. CITY OF HOPE'S AUDIT COMMITTEE ALSO SERVES AS THE AUDIT COMMITTEE OF BECKMAN RESEARCH INSTITUTE. ADDITIONALLY, THE PREPARATION OF THE FORM 990 IS DONE INTERNALLY AND IS REVIEWED THOROUGHLY WITH INTERNAL LEADERSHIP AND EXTERNAL PARTICIPANTS, INCLUDING EY, which is the preparer, AND RETAINED OUTSIDE TAX COUNSEL. PRIOR TO FILING, THE BECKMAN RESEARCH INSTITUTE FORM 990 IS MADE AVAILABLE TO VOTING MEMBERS OF THE CITY OF HOPE BOARD OF DIRECTORS FOR REVIEW ELECTRONICALLY. FORM 990, PART VI, SECTION B, LINE 12C ALL EMPLOYEES OF CITY OF HOPE AND AFFILIATES, MEMBERS OF THE BOARDS OF DIRECTORS, BOARD COMMITTEE MEMBERS AND RESEARCH TEAM MEMBERS ARE COVERED BY CITY OF HOPE'S APPLICABLE CONFLICT OF INTEREST POLICIES. DETERMINATIONS AS TO WHETHER A CONFLICT OF INTEREST EXISTS AND REVIEW OF SUCH CONFLICT DISCLOSURES ARE MADE BY GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER AND, AS APPLICABLE, THE CHAIR OF THE BOARD OR BOARD OF DIRECTORS OR THE CONFLICT OF INTEREST AND COMMITMENT COMMITTEE, BASED UPON THE CATEGORY OF PERSON MAKING THE DISCLOSURE. RESTRICTIONS IMPOSED ON PERSONS TO MANAGE A CONFLICT VARY, BASED UPON THE FACTS AND MAY INCLUDE: PROHIBITION FROM PARTICIPATING IN A GOVERNING BODY'S DELIBERATIONS AND VOTING ON A GIVEN TRANSACTION OR SET OF TRANSACTIONS; RECUSAL FROM THE DECISION-MAKING PROCESS RELATING TO BUSINESS TRANSACTIONS (E.G., PURCHASING DECISIONS); PROHIBITION FROM PARTICIPATING AS A PRINCIPAL INVESTIGATOR IN RESEARCH; AND DISCLOSURE OF FINANCIAL INTEREST IN RESEARCH STUDY INFORMED CONSENT FORMS AND PUBLICATIONS. MONITORING TRANSACTIONS FOR CONFLICTS OF INTEREST IS DONE THROUGH ANNUAL REQUIRED DISCLOSURES AND UPDATES BY PERSONS COVERED BY THE ORGANIZATION'S CONFLICT OF INTEREST POLICIES AND A CONCURRENT REVIEW OF SUCH DISCLOSURES AGAINST TRANSACTIONS. CITY OF HOPE POLICY PROVIDES FOR DISCIPLINARY ACTION AGAINST PERSONS COVERED BY THE CONFLICT OF INTEREST POLICIES WHO DO NOT COMPLY WITH POLICY REQUIREMENTS. FORM 990, PART VI, SECTION B, LINES 15A AND 15B The Executive Compensation and Governance Committee of City of Hopes Board of Directors (Committee), pursuant to a delegation of authority from the Board, is responsible for setting the compensation of the CEO and certain other senior executives. THE COMMITTEE ALSO SERVES AS THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE BECKMAN RESEARCH INSTITUTE. The Directors on the Committee are independent and adhere to a strict conflict of interest policy and deliberation and decision making are substantiated in the minutes of the Committees meetings. The minutes are reviewed and approved at the next meeting of the Committee. As part of the deliberation process, the Committee receives advice from an independent, third-party compensation consultant with respect to executive compensation, including review of comparable and benchmark data, current compensation philosophy, structure, and administration of the executive cash compensation programs at City of Hope and affiliates. The Committee carries out the Board of Directors overall responsibilities relating to executive compensation. The executive compensation philosophy is designed to assist in attracting and retaining the caliber of executive leadership required to enable City of Hope to achieve the highest levels of community benefit, impact to clinical care, quality research and efficient philanthropic development. The Committee targets the 50th percentile of base salary and the 75th percentile of total cash compensation of the market in which City of Hope competes for executives. Under an Annual Incentive Plan (AIP) and a Long Term Incentive Plan (LTI), a substantial portion of executive compensation is linked directly to performance goals approved in advance by the Committee. As a result, performance compensation may vary from year to year. Goal setting under the AIP is tied to annual performance, including the attainment of specific business objectives for strategic and financial performance as well as non-financial measures such as patient satisfaction and quality of patient care. The LTI is designed to drive long-term organizational performance and transformation by aligning executives with the multi-year strategic plan and incentivizing them for achieving key organizational and strategic objectives and goals. With three-year vesting periods, the LTI also provides a means for retaining key executive talent. The Committee conducts annual compensation reviews for executives and certain key employees and this was last completed on December 23, 2016. The compensation programs and ranges for all officers and key employees listed on From 990, Part VII at the SVP or equivalent level and above are reviewed by this Committee. FORM 990, PART VI, SECTION C, LINE 19 BECKMAN RESEARCH INSTITUTE'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE. CITY OF HOPE AND AFFILIATES' AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE CITY OF HOPE WEBSITE, AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CONFLICT OF INTEREST MANAGER. BECKMAN RESEARCH INSTITUTE'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990, PART VII, COLUMN (B) FULL TIME EXEMPT EMPLOYEES GENERALLY WORK IN EXCESS OF 40 HOURS PER WEEK, WHICH HAS BEEN REFLECTED IN PART VII BY AN ESTIMATE OF 60 HOURS PER WEEK. THE MEMBERS OF THE BOARD OF DIRECTORS ARE NOT COMPENSATED FOR SERVING ON THE BOARD. THE HOURS WORKED FOR EACH DIRECTOR IS AN ESTIMATE OF THE TIME SPENT PREPARING FOR AND ATTENDING MEETINGS OF THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS HELD THREE REGULARLY SCHEDULED MEETINGS DURING FISCAL YEAR 2016. THE AUDIT AND COMPLIANCE COMMITTEE HELD 6 REGULARLY SCHEDULED MEETINGS IN FISCAL YEAR 2016. MOST OF THE CITY OF HOPE OFFICERS AND KEY EMPLOYEES, AS WELL AS A FEW OF ITS HIGHEST COMPENSATED EMPLOYEES, PROVIDE SERVICES TO MORE THAN ONE CITY OF HOPE ENTITY, AND MANY OF THEM PROVIDE SERVICES TO ALL OF THE ENTITIES. FOR A NUMBER OF THESE CONCURRENTLY-EMPLOYED INDIVIDUALS, THE ENTITIES HAVE DESIGNATED THE MEDICAL CENTER AS THE "COMMON PAYMASTER" AS IS DEFINED IN SECTION 3121(S) OF THE INTERNAL REVENUE CODE. CITY OF HOPE REPORTS THESE CONCURRENT EMPLOYEES' TIME, EFFORT AND COMPENSATION ON THE INFORMATION RETURNS OF THE CITY OF HOPE ENTITIES BASED ON THE ESTIMATES OF THEIR TIME SPENT IN AND FOR EACH ENTITY. AS "COMMON PAYMASTER," THE MEDICAL CENTER ISSUES EACH OF THESE EMPLOYEES A SINGLE, COMBINED PAYCHECK AND ONE FORM W-2. FORM 990, PART XI,LINE 9 CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT (2,959,141) UNCOLLECTIBLE GRANTS (73,597) ____________ TOTAL LINE 9 CHANGES (3,032,738) CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(C)3 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(C)3 3 CITY OF HOPE true City of Hope Medical Foundation 1500 E Duarte Road Duarte CA 91010 274803222 Healthcare CA 501(C)3 3 City of Hope true false false true false false false false false false false false true true false true true true false false CITY OF HOPE NATIONAL MEDICAL CENTER P 33958114 FMV CITY OF HOPE NATIONAL MEDICAL CENTER Q 8096977 FMV CITY OF HOPE NATIONAL MEDICAL CENTER O 22196741 FMV CITY OF HOPE NATIONAL MEDICAL CENTER M 28069068 FMV CITY OF HOPE NATIONAL MEDICAL CENTER L 1021006 FMV CITY OF HOPE MEDICAL FOUNDATION Q 103259 FMV